Influenza viral protein synthesis

Influenza viral protein synthesis is the essential biological process by which the influenza virus hijacks host cellular machinery to produce the structural and functional proteins required for viral replication (Das et al., 2010). The process initiates with the transcription of viral negative-sense RNA into messenger RNA (mRNA) by the viral RNA-dependent RNA polymerase (RdRp) complex, which utilizes a unique "cap-snatching" mechanism (Hayden et al., 2018). These viral mRNAs are then translated by host ribosomes into polypeptides, including Hemagglutinin (HA), Neuraminidase (NA), and Matrix proteins. Post-translational maturation, particularly the folding and glycosylation of HA, is a critical subsequent step occurring within the host's secretory pathway (Rossignol, 2014). Pharmacological intervention can occur at several stages: Baloxavir marboxil inhibits the PA subunit's endonuclease activity to block mRNA synthesis, while Nitazoxanide interferes with the maturation of the HA protein (Rossignol, 2014; Hayden et al., 2018). Other inhibitors, such as Pimodivir, target the PB2 subunit to prevent viral RNA recognition (Trevejo et al., 2018). Because the virus relies on host ribosomes for translation, achieving therapeutic selectivity is a major challenge, necessitating the targeting of viral-specific enzymes or maturation processes. Monitoring efficacy typically involves measuring viral RNA loads or protein expression levels in infected tissues. The emergence of resistance mutations, such as the I38T substitution in the PA protein, remains a significant concern for drugs targeting this pathway (Hayden et al., 2018).

Other names

Influenza virus translationViral protein productionInfluenza mRNA translationViral protein maturation

Inhibition of viral mRNA synthesis via cap-snatching endonuclease inhibition, inhibition of the RNA-dependent RNA polymerase complex, or disruption of post-translational maturation of viral glycoproteins.